FRED HUTCHINSON CANCER CENTER
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia is a funding opportunity from FRED HUTCHINSON CANCER CENTER, up to 719414, closing July 31, 2028.
Jul 31, 2028
(731d left)Overview
SUMMARY Many cancers carry recurrent, change-of-function mutations affecting RNA splicing factors, resulting in sequence-specific changes in RNA splicing that promote disease initiation and progression. These “spliceosomal mutations” are the most common class of mutations in myelodysplastic syndromes (MDS) and…